Endocrinology Vol. 138, No. 3 1151-1158
Copyright © 1997 by The Endocrine Society
Cloning, Novel Promoter Sequence, and Estrogen Regulation of a Rat Oxytocin Receptor Gene1
Tracy L. Bale and
Daniel M. Dorsa
Departments of Pharmacology and Psychiatry and Behavioral Sciences,
University of Washington, Seattle, Washington 98195
Address all correspondence and requests for reprints to: Tracy L. Bale, Box 357280, Department of Pharmacology, University of Washington, Seattle, Washington 98195. E-mail: tbale{at}u.washington.edu
 |
Abstract
|
|---|
Expression of the oxytocin receptor (OR) gene in vivo is
known to be regulated by estradiol (E2). We have cloned and
sequenced 4 kilobases (kb) of 5'-flanking DNA of the rat OR gene and
identified an internal segment of 1260 nucleotides that was absent in
an initial publication of this promoter and an additional 2 kb of
upstream sequence. This novel internal region is located between two
large tg nucleotide repeats. PCR amplification using genomic DNA
verified that this sequence is present in the rat genome. To explain
transcriptional effects of E2, a palindromic estrogen
response element (ERE) that is active in estrogen receptor binding was
identified within this new sequence, approximately 4 kb 5' of the
translational start site. The ability of E2 to enhance
transcription of this promoter was tested in transfection experiments
in MCF7 cells. E2 only weakly induced transcription of a
truncated construct. Mutational analysis of the ERE in the context of a
basal promoter indicated that it functions as an enhancer, and that
mutation of two bases eliminates this activity. Further support of the
efficacy of this response was shown in mobility gel shift assays in
which the OR ERE bound estrogen receptor present in uterine extracts.
Receptor binding studies using 125I-ornithine vasotocin in
MCF7 cells revealed that E2 dramatically up-regulated
endogenous ORs. Western blot analysis confirmed this increase in OR
protein with E2 treatment of MCF7 cells. These studies have
identified a novel region of the rat OR promoter containing an upstream
palindromic ERE that imparts E2 inducibility of OR gene
transcription.
 |
Introduction
|
|---|
THE NEUROPEPTIDE oxytocin (OT)
functions in important roles in both the periphery, as a
neurohypophyseal hormone involved in lactation and parturition (1), and
in the central nervous system, as a neurotransmitter involved in sex
behavior and maternal aggression (2, 3, 4, 5, 6). Radioligand binding studies in
rat brain have localized oxytocin receptors (ORs) to several regions,
including the hippocampus (7, 8), paraventricular nucleus (9), and
ventromedial hypothalamus (VMH) (10, 11, 12). Further, in situ
hybridization studies have localized an abundance of OR messenger RNA
(mRNA) in the VMH (13). Both OR binding and mRNA studies have
demonstrated that receptor expression is sensitive to gonadal steroids.
Specifically, estrogen has been shown to increase the number of
OR-binding sites and the mRNA level in the myometrium of the uterus
(14, 15) and in the VMH of male and female brains (11, 12, 13, 16, 17, 18, 19, 20). In
females, the localization and density of OR mRNA in the VMH vary during
the estrous cycle, particularly on the afternoon of proestrus when
estrogen levels are maximal (21). Both the rat and human OR genes have
been cloned and their 5'-flanking regions analyzed for regulatory
elements (22, 23, 24). To date, no palindromic estrogen response elements
(ERE) have been reported in the OR promoter; however, the presence of
several half-EREs has been noted (22, 24). Transcriptional enhancement
or protein binding capabilities of these half-elements have not been
shown.
To determine how estrogen might influence transcription of the OR gene,
we isolated and sequenced 4.5 kilobases (kb) of upstream sequence of a
rat genomic clone. In doing so, we discovered a discrepancy in nucleic
acid content and length between our clone and that which was previously
reported (22). This novel promoter sequence was then analyzed for
regulatory elements and used in transfection assays to determine OR
gene regulation by estrogen.
 |
Materials and Methods
|
|---|
Screening and sequencing procedures
A
phage GT10 rat genomic testes library was screened using
oligonucleotides based on human OR sequence. Positive clones were
digested with EcoRI and analyzed by Southern blotting.
Membranes were probed with the same 32P-labeled
oligonucleotides used for screening. Positive fragments were then
isolated, purified, and subcloned into pGEM7 (Promega). Sequencing was
performed according to the Sequenase (U.S. Biochemical Corp.,
Cleveland, OH) protocol, using primers corresponding to flanking vector
sequences and internal rat DNA sequences.
Verification of novel sequence in rat genome
As the genomic clone examined contained an additional
sequence internal to that reported by Rozen et al. (22),
oligonucleotides were synthesized by PCR to verify the presence of our
novel sequence in rat genomic DNA. Genomic DNA isolated from brain
tissue in two rat strains (Long-Evans and Sprague-Dawley) was used for
amplification. The sense oligonucleotide was located within the novel
sequence (nucleotide 33963416, 5'-ACATACGTGGTGCTGCAGCC-3'), whereas
the antisense oligonucleotide was located within a previously
reported sequence (nucleotide 43044324,
5'-AAAGTGGTTCATCGCAAGCCT-3'). The control reaction contained
oligonucleotides synthesized from the coding region sequence (sense,
oligonucleotides 45304550; antisense, oligonucleotides 59005920).
The PCR reaction was carried out under standard conditions for
Perkin-Elmer thermocycling: 1.5 mM MgCl2,
1 x PCR buffer, 0.5 µM oligonucleotide DNA, 1 µg
template DNA, and 0.25 mM nucleotides in a 100-µl
reaction for 35 cycles at temperatures of 95 C for 2.5 min, 57 C for
2.0 min, and 72 C for 1.5 min. PCR products were run on a 1% agarose
gel for size determination. Further PCR amplification included using
sense and antisense primers based on a previously reported sequence
that was amplified across the internal region of the novel
sequence.
Reporter gene constructs
Three reporter constructs were designed for use in
transfection experiments (see Fig. 3
). Portions of the OR promoter were
subcloned into the luciferase plasmid pGL2B (Promega, Madison, WI). As
shown in Fig. 3
, clone ORfp contained the full-length promoter, 4.5 kb
upstream of the ATG translation start site. DNA clone ORp+
was a truncated form of the promoter, with an internal deletion of 3480
bp, bringing the upstream palindromic ERE into closer proximity to the
transcription start site, previously reported by Rozen et
al. (22). Clone ORp- was the same clone as
ORp+, except the upstream region containing the ERE was
removed by restriction enzyme digestion (NdeI).

View larger version (9K):
[in this window]
[in a new window]
|
Figure 3. Reporter gene constructs of the rat OR used for
transfection experiments. The name and length of the construct are
indicated at the left. The shaded circle
represents palindromic ERE. Boxes represent tg repeats;
checkered boxes illustrate where truncated constructs
were ligated, with sequence between checkered boxes thus eliminated.
Corresponding nucleic acid sequence numbers are found
below each diagram.
|
|
Promoter constructs containing wild-type or mutant forms of the
OR ERE were made using PCR amplification from the original OR clone in
pGEM7 with oligonucleotides complementary to bases 556582 (antisense)
and the T7 promoter/primer (Promega; sense). The antisense
oligonucleotides were synthesized with a KpnI restriction
enzyme site at the 3'-end (5'-AGGGCTAGCTGGGTCATCTGGACCAA-3', wild type,
ERE+) in addition, the mutant construct had two bases
within the ERE mutated (5'-AGGGCTAGCTGGATCATCTGGACAAA-3', mutant,
ERE-). Both mutant and normal PCR products were
restriction enzyme digested with KpnI and NheI
(Promega), gel purified, subcloned into the enhancer site of the
luciferase simian virus 40 promoter plasmid pGL3 (Promega), and used in
transfection experiments as described below.
Transfection experiments
Transfection was performed by introduction of 3 µg
plasmid DNA/well into six-well plates containing MCF7 cells at 80%
confluency using the lipid transfection agent, DOTAP (Boehringer
Mannheim, Indianapolis, IN). Cells were treated with steroid hormone
for 8 h and harvested after 15-min incubation in lysis buffer
(Promega), unless otherwise specified. Cell extracts were used in
luciferase assays according to the Promega luciferase assay protocol.
The native pGL2 plasmid was used as a negative control for these
experiments, such that each wells luciferase activity was subtracted
by the negative controls luciferase activity for each experiment. For
experiments involving the ERE as an enhancer in the pGL3 plasmid, the
negative control was the native pGL3 plasmid. Results were normalized
by cotransfection of ß-galactosidase DNA, such that for each well the
resulting luciferase light units were divided by the ß-galactosidase
activity for that well.
OR binding
Binding was performed on whole cell extracts from treated MCF7
cells. Cells were distributed into the desired number of flasks, with
equal numbers of cells per flask. Flasks were randomly assigned to
treatment groups and were treated at 9095% confluence for 24 h.
Cells were harvested (2.53 x 106 cells/flask) by
trypsinization, pelleted by centrifugation, resuspended in PBS for
washing, repelleted by centrifugation, and resuspended in a final
volume of 3 ml PBS. Cells were frozen at -80 C until assay was
performed.
Binding was performed using a cell harvester apparatus. GF-C membranes
(Whatman, Clifton, NJ) were used for attachment of cells on harvester.
Membranes were soaked in PBSBT (0.1% BSA, 0.02% tyrosine, and 0.1%
MgCl2 in PBS) plus 6 mg/ml BSA and 1 µm OT at room
temperature for 30 min. Binding reactions consisted of triplicate
samples for specific and nonspecific conditions for each cell
treatment. Each reaction contained approximately 2.5 x
105 cells, 0.03 nM
[125I]ornithine vasotocin (OTA) (New England Nuclear,
Boston, MA), and PBSBT buffer to a volume of 500 µl. Nonspecific
samples also contained 1 µM unlabeled OT. Reactions were
incubated for 15 min at 37 C before loading onto the harvester. Before
loading cells, membranes were first rinsed with 250 ml of 0.2%
polyethyleneimine. After cells were loaded onto membranes, incubation
tubes and membranes were rinsed four times with 3 ml 50 mM
Tris, pH 7.5. Membranes were then counted on a
-counter for
quantitation of bound [125I]OTA. Averages of triplicates
for nonspecific binding values were subtracted from averages of
specific binding values for each treatment to determine specific
binding.
Western blot analysis
MCF7 cells were treated with vehicle (ethanol) or 10
nM estradiol (E2) for 24 h, then harvested
by trypsinization and resuspended in 10 mM Tris-HCl (pH
7.4), 100 mM NaCl, and 1 mM dithiothreitol
containing aprotinin (10 µg/ml), leupeptin (10 µg/ml), and
pepstatin (1 µM; homogenization buffer). Cells were
homogenized and centrifuged for 5 min at 700 x g, and
the supernatant was removed and centrifuged at 100,000 x
g for 30 min. Membrane pellets were resuspended in 1 ml
homogenization buffer, and the protein concentration was determined by
Bradford analysis. Membrane proteins (10 µg/lane) were separated by
SDS-PAGE on a 10% Laemmli minigel and electrotransferred to
nitrocellulose in a semidry transfer apparatus (Bio-Rad Laboratories,
Richmond, CA) for 2 h at 15 V (constant voltage) with 25
mM Tris (pH 8.3), 192 mM glycine, 20%
methanol, and 0.004% SDS as the transfer buffer. Unbound sites were
blocked overnight at 4 C in 10 mM Tris and 0.15
M NaCl (pH 7.4; TBS) containing 5% (wt/vol) skim milk
powder. Blots were washed three times for 10 min each time with TBS
containing 0.05% Tween-20 (TBST) and incubated for 1 h with a
1:10,000 dilution of anti-OR antibody (25) in TBST. Blots were then
washed three times for 10 min each time with TBST and incubated with
horseradish-linked goat antirabbit antibody (1:20,000) in TBST for
1 h. Blots were again washed three times with TBST as described
above, and immunoreactive bands were visualized using the Amersham ECL
immunoblotting detection system (Amersham Corp., Arlington Heights,
IL).
Mobility gel shift
The oligonucleotides synthesized were: the ERE of the
vitellogenin promoter as a positive control
(5'-GATCCAGGTCACTGTGACCTG-3'), the ERE for the OR
(5'-CCTTGGTCCAGATGACCCAGC-3'), and a scrambled form of the OR ERE as a
negative control (5'-CACTCGACATCAGCGTGTCGC-3'). Cytosolic extracts of
parturient uterine tissue were prepared as reported previously (26).
Aliquots of extracts were incubated with 250 ng poly(dI-dC) in 20 µl
buffer [10 mM Tris-HCl (pH 7.5), 1 mM
dithiothreitol, 100 mM KCl, 10% glycerol, and 3 µg/µl
BSA] plus 32P 5'-end-labeled oligonucleotides (20,000 cpm)
for 15 min at room temperature (27). Complexes were resolved by
electrophoresis at 4 C on a 5% nondenaturing acrylamide gel
equilibrated in 0.5 x TBE (5 mM Tris and 0.5
mM EDTA). For supershift assays, 1 µl of antiestrogen
receptor (anti-ER) antibody (SRA1000, Stressgen, Vancouver, British,
Columbia) was preincubated with cell extract overnight at 37 C before
adding labeled oligonucleotides.
 |
Results
|
|---|
Identification of novel sequence
During sequencing to obtain additional 5'-promoter sequence
for transfection studies, important differences were noted between our
OR clone and that previously described (22). Primers designed for
sequencing based on sequence from Rosen et al. (22) as well
as those directed from previously unknown internal sequence toward
published sequence in both 5'- and 3'-directions produced sequence in
the 3'-direction that was not in the previous report. Continued
sequencing revealed a third tg repeat and a 1.26-kb novel internal
segment (nucleotides 30104232 in Fig. 1
).

View larger version (82K):
[in this window]
[in a new window]
|
Figure 1. 5'-Flanking sequence for rat OR. Putative
response elements are in boldface, with their respective
identification labeled above the sequence.
Arrows following or preceding identification indicate
the direction of the element based on the consensus sequence. TG
repeats are in italics. The translation start site (ATG)
is also in bold print and underlined.
Asterisks are located above previously identified (22)
transcription start sites.
|
|
Verification of sequence in rat genome
To confirm the presence of our clone in the rat genome, we
performed PCR using primers corresponding to the newly identified
sequence as well as to that specified in the original publication (22).
All PCR experiments indicated that the novel sequence was present
in the rat genome, as evidenced by amplification of the predicted
products based on our sequence data. A forward primer based on the
novel internal sequence and a reverse primer based on the original
published sequence were used to amplify a product 948 bp in length
using genomic DNA from both Sprague-Dawley and Long-Evans rat strains
(Fig. 2
, A and B). DNA from two rat strains were used to
verify that the discrepancy in sequence data was not due to a
difference in OR genes between rat strains. A control PCR reaction was
used to amplify coding region product of known length (Fig. 2C
).
Further PCR reactions were performed to determine whether both this
novel gene and the originally reported gene were present in the genome,
suggesting the presence of two rat OR genes. None of these reactions
yielded PCR products consistent with the previously reported sequence.
The length of novel sequence is 1.26 kb and lies between the first two
large tg repeats found in the 5'-flanking region of this genomic clone
(Fig. 1
).

View larger version (73K):
[in this window]
[in a new window]
|
Figure 2. Products from PCR amplification of Sprague-Dawley
(A) and Long-Evans (B and C) genomic DNA. Amplification was performed
using primers complementary to nucleotides 33963416 (sense) to
43244344 (antisense) in novel sequence (A and B) and control reaction
using primers complementary to nucleotides 45304550 (sense) to
59005920 (antisense) in the coding region (C).
|
|
Novel internal and distal sequence of the rat OR promoter
In addition to the novel internal sequence described above,
we also included an additional 2 kb of sequence 5' of the that
previously reported (Fig. 2
). This distal sequence contains several
potential transcription factor-binding sites, including several
activating protein-1 (AP-1), AP-2, AP-3, and AP-4 sites and a
half-serum response element site. Included in the novel internal
sequence was a cAMP response element (CRE). A palindromic ERE,
differing by 1 base from the consensus, was found 4 kb 5' of the
translation start site. No typical CCAAT box was found in the novel
sequence; however, a TATA-like motif was localized to a region
approximately 100 bp from the transcription start site identified
previously by Rozen et al. (22) using rapid amplification of
3'-cDNA ends cloning. Other putative elements of interest in the novel
sequence include several half-glucocorticoid response elements and
retinoic acid response elements.
Effects of estrogen on reporter gene constructs
Several different reporter gene constructs were created for use in
transfection experiments to assess the effects of E2 on OR
promoter activity (Fig. 3
). Our initial experiments used
the full-length construct (ORfp), and the two truncated constructs
(ORp+ and ORp-), which enabled us to examine
the potential activity of the palindromic ERE located 4 kb upstream.
Basal transcription was consistently enhanced in the full-length
construct. In a typical experiment, when corrected for transfection
efficiency, basal luciferase activity for the full-length construct in
MCF7 cells was 2000 vs. 250 light units for the luciferase
plasmid alone. Little induction in response to E2 treatment
was evident in the full-length (ORfp) construct. In contrast, exposure
to 10 nM E2 promoted a small, but consistent,
1.5-fold induction over vehicle levels of the ORp+
construct in MCF7 cells. This response was absent in the
ORp- construct in which the upstream ERE-containing
segment had been removed (Fig. 4
). Transfection assays
using increasing concentrations of E2 (from 10200
nM) showed no further effect on transcription (data not
shown). As these truncated constructs were determined to not contain
the newly identified TATA-like motif, we tested the induction
capability of the ERE by subcloning it as an enhancer into a basal
simian virus 40 reporter construct (pGL3).

View larger version (24K):
[in this window]
[in a new window]
|
Figure 4. Graph illustrating fold induction over vehicle for
OR reporter gene constructs in MCF7 cells with treatment of 10
nM E2. Truncated ORp+,
ORp-, and full-length ORfp constructs were tested. All
treatments were performed for 8 h. Data are reported as the
average of at least three experiments ± SEM.
|
|
Transfection experiments using the OR ERE-pGL3 construct showed
that when placed in the enhancer region upstream of a basal simian
virus 40 promoter, this ERE increased transcription in the presence of
E2 in a concentration-dependent manner, which became
maximal at 200 nM (Fig. 5
). Mutation of only
2 bases in this ERE completely eliminated its ability to act as an
enhancer after E2 treatment.

View larger version (35K):
[in this window]
[in a new window]
|
Figure 5. Graph illustrating fold induction over vehicle for
ERE+ (wild-type) reporter gene construct in MCF7 cells with
increasing concentrations of E2 (10, 20, 50, 100, and 200
nM). ERE- (mutant form of ERE+)
showed no induction above vehicle. All measurements were made 24 h
after E2 addition. Data are reported as the average of at
least three experiments ± SEM.
|
|
Receptor binding experiments
E2 (10 nM) treatment of MCF7 cells
increased the specific binding of [125I]OTA 17-fold over
that measured in vehicle-treated cells (Fig. 6
). Levels
of specific binding in vehicle-treated cells were low (37.6 cpm/tube),
indicating a low basal state of expression of the OR in these
cells.

View larger version (13K):
[in this window]
[in a new window]
|
Figure 6. Effects of vehicle or estrogen (10 nM)
treatment on specific [125I]OTA binding in MCF7 cells.
Cells were treated for 24 h before harvesting. Binding of
[125I]OTA was performed for 15 min at 37 C. The
concentration of ligand was 0.03 nM. Nonspecific binding
was measured by the addition of 1 µM OT. Each reaction
tube contained approximately 2.5 x 105 cells. Data
are reported as the average of triplicate determinations in two
separate experiments ± SEM.
|
|
Western blot analysis
E2 (10 nM) treatment of MCF7 cells also
increased OR protein, as shown by an increase in a specific band of
approximately 70 kDa recognized by OR antibody 3580 (25) (Fig. 7
). This band has a mol wt similar to that previously
shown for the OR (28, 29).

View larger version (54K):
[in this window]
[in a new window]
|
Figure 7. Western blot autoradiograph showing an increase in
OR protein as measured by OR antibody 3980 (25) when comparing vehicle
treatment (A) to 10 nM E2 treatment (B) of MCF7
cells. Treatments were performed for 24 h.
|
|
Mobility gel shift
To determine whether the palindromic ERE identified in the distal
segment of this clone was functional in ER binding, we conducted
mobility gel shifts using cell extracts from a parturient rat uterus.
Results from this gel shift indicated that the OR ERE binds ER, and
this binding can be eliminated by preincubation with an anti-ER
antibody (Fig. 8
). The OR ERE (OR-ERE)
showed a somewhat lower binding affinity for the ER than the
vitellogenen ERE, but was much greater than the scrambled sequence
negative control. The anti-ER antibody abolished protein binding to
both the vit-ERE and the OR-ERE.

View larger version (41K):
[in this window]
[in a new window]
|
Figure 8. Autoradiogram of mobility gel shift assay for ER
binding. The control oligonucleotide is vitellogenin ERE (Vit ERE). The
ERE from OR promoter (OR ERE) and a scrambled OR ERE of the same
nucleotide content and length (ScrERE) were used. ER antibody (SRA
1000) was used (Ab).
|
|
 |
Discussion
|
|---|
We have identified a novel segment of internal sequence in
5'-flanking DNA of a rat OR gene that was missing from that reported by
Rozen et. al (22). Additional upstream sequence for this putative
promoter is also included in this report. These new segments of
sequence contain several interesting response elements, including a
palindromic ERE, cAMP response element, half-serum response element,
and several AP-1, AP-2, AP-3, and AP-4 sites. PCR amplification
verified the presence of this novel promoter sequence in the genome of
both Sprague-Dawley and Long-Evans rat strains. The novel segment of
sequence reported in this study is flanked by extensive tg repeats. It
is possible that these tg repeats caused DNA folding, which may have
resulted in a looping out and loss of this segment during bacterial
transformation and replicating procedures employed in the original
cloning procedure (22). PCR amplification using primers that should
have produced two different sized bands if both genes were present in
the genome only yielded a band of the correct size based on our
sequence and not the previously reported sequence. Further attempts to
amplify bands of the size predicted by the former sequence were also
unsuccessful. Thus, it appears that the previously reported promoter
sequence is missing 1260 bases, a deletion that may have occurred
during bacterial replication.
Transfection experiments in MCF7 cells using the OR 5'-flanking DNA,
including the newly identified segments, demonstrated that this
promoter exhibits both basal and inducible transcriptional activity.
E2 exposure produced a variable response in MCF7 cells,
enhancing transcription of the truncated ERE-containing construct
(ORp+) 1.5 times that of vehicle, whereas induction was
absent in the same construct lacking the ERE (ORp-). No
induction of transcription by E2 was noted when the
full-length construct (ORfp) was tested, suggesting that proximity of
the distal ERE to the basal transcriptional machinery may be essential
for E2 inducibility.
Although the in vitro reporter gene assays failed to show
the expected large induction of transcription by E2, the
receptor binding studies demonstrated that E2 can increase
the number of endogenous OR-binding sites in MCF7 cells. Measurement of
specific binding in vehicle- and E2-treated cells using
[125I]OTA revealed a dramatic increase (17-fold) in OR
binding. These results were supported by an increase in OR protein with
E2 treatment of MCF7 cells, as shown by Western blot
analysis. It has previously been shown that MCF7 cells endogenously
express ORs, but only at levels that require extremely sensitive
methods for detection (30, 31, 32, 33). The increase in OTA-binding sites and
protein induced by E2 in these cells supports in
vivo data suggesting that transcription of this gene can be
regulated by E2. These data also argue that the small
estrogenic induction of transcription of the OR reporter constructs we
have seen cannot be attributed to the use of a heterologous cell line
that does not express ORs or the factors necessary to induce
transcription of the OR gene.
Mobility gel shift assays showed that the OR ERE does bind ER, and this
shifted complex can be eliminated by an anti-ER antibody. This
protein-binding activity was specific, as no binding was seen for a
scrambled oligonucleotide composed of the same length and gc content.
Because the truncated reporter constructs used did not contain the
newly identified TATA-like motif, we assessed the enhancer activity of
the upstream palindromic ERE in a basal promoter. Interestingly, in the
context of a basal promoter, the OR ERE-induced transcription in an
E2 concentration-dependent manner, whereas a mutant form of
this ERE was nonresponsive to E2. These results suggest
that if this ERE is involved in E2-induced gene
transcription, it may be necessary that it be brought into closer
proximity to the basal transcriptional apparatus, perhaps through DNA
folding.
Several other genes known to be strongly regulated by E2in vivo exhibit only weak E2 inducibility
when exposed to E2 in vitro (27, 34). These
results suggest several hypotheses. First, the effect of E2in vivo may be indirect and may be mediated by
activation of protein kinase C and/or protein kinase A pathways.
Several studies have been reported that support this possibility
(35, 36, 37, 38). Alternatively, the effects of E2 in
vivo may not be mimicked in vitro due to a requirement
for a specific DNA configuration not achievable in our plasmid
constructs. We have noted evidence of secondary structure formation
caused by the three large tg repeat segments in this promoter. It is
conceivable that these tg repeats serve important roles in promoter
function and may allow response elements that are more distal to the
transcription start site to be brought into closer proximity. Evidence
for Z-DNA structure folding associated with promoter activation has
been suggested for other genes, including the rat cholesterol
7
-hydroxylase gene (39). Steroid hormones are known to influence the
formation of secondary structure required for promoter activity. For
example, the chromatin structure of the mouse mammary tumor virus is
dependent not only on the presence of certain steroid hormones, but
also on the cell type and receptor status of the recipient cell into
which it is transfected (40, 41, 42). Based on these reports, it is
possible that the OR gene may rely on an induced secondary structure
formed by the three tg repeats to exhibit E2 induction.
Lastly, it is reasonable to suggest the existence of a second OR gene,
which may be responsive to E2. The existence of two OR
genes might also provide an explanation for discrepancies that have
been reported between OR mRNA and protein localization in the brain. OR
binding studies have shown that OR binding is eliminated in the VMH
when female or male rats are gonadectomized, whereas binding is not
affected in the central nucleus of the amygdala (12, 43). It is
possible then that the gene we have isolated and studied here is that
which is responsible for this amygdala expression and, therefore, does
not require E2 for its induction.
In summary, we have sequenced and analyzed the rat OR promoter,
including a novel 1.26-kb segment that had been deleted from the
original published rat OR sequence, in addition to 2 kb of promoter
sequence 5' of that previously reported (22). Sequence analyses
revealed a palindromic ERE in addition to numerous potential response
elements within this sequence. Reporter constructs of this promoter
demonstrated only a small transcriptional response to E2.
However, reporter constructs containing the OR ERE as an enhancer in
the context of a basal promoter demonstrated an
E2-concentration dependent induction. The palindromic ERE
identified in the distal portion of the OR promoter showed ER-binding
activity in gel shift assays. Receptor binding and Western blot assays
showed that E2 treatment of MCF7 cells increased endogenous
OR levels. Further studies are required to fully characterize modes of
transcriptional regulation of this gene and their potential roles in OR
expression in the brain and periphery.
 |
Acknowledgments
|
|---|
The authors thank Cong Xu for her excellent technical support,
Bryce Wallace and Meg Barclay for their laboratory assistance, Dr.
Brian J. Murphy for critical reading of the manuscript, and Dr. Joseph
Verbalis, Georgetown University (Washington DC), and Dr. Gloria
Hoffman, University of Maryland (Baltimore, MD), for their generous
gift of OR antibodies.
 |
Footnotes
|
|---|
1 This work was supported by USPHS Grants NS-20311 and AG05136, and
Molecular and Cellular Biology Training Grant T32-GM-07270. 
Received October 7, 1997.
 |
References
|
|---|
-
Smith MS 1989 Lactation. In: Patton HD,
Fuchs AF, Hille B, Scher AM, Steiner RS (eds) Textbook of Physiology.
Saunders, Philadelphia, vol 2:14081421
-
Pedersen CA, Prange AJ Jr 1979 Induction of
maternal behavior after intracerebroventricular administration of
oxytocin. Proc Natl Acad Sci USA 76:66616665[Abstract/Free Full Text]
-
Fahrbach SE, Morrell JI, Pfaff DW 1985 Possible
role of endogenous oxytocin in estrogen-facilitated maternal behavior
in rats. Neuroendocrinology 40:526532[Medline]
-
Van Leengoed E, Kerker E, Swanson HH 1987 Inhibition of post-partum maternal behavior in the rat by injecting an
oxytocin antagonist into cerebral ventricles. J Endocrinol 112:275282[Abstract/Free Full Text]
-
Caldwell JD, Prange AF, Pedersen CA 1986 Oxytocin
facilitates the sexual receptivity of estrogen-treated female rats.
Neuropeptides 7:175189[CrossRef][Medline]
-
Schumacher M, Coirini H, Frankfurt M, McEwen BS 1989 Localized actions of progesterone in hypothalamus involve
oxytocin. Proc Natl Acad Sci USA 86:67986801[Abstract/Free Full Text]
-
Van Leeuwen FW, Van Heerikhuize JJ, VanDerMeulen G,
Wolters P 1985 Inhibition of postpartum maternal behavior in the
rat by injecting an oxytocin antagonist into cerebral ventricles. J
Endocrinol 112:275282
-
Tribollet E, Barberis C, Jard S, Dubois-Dauphin M,
Dreifuss JJ 1988 Localization and pharmacological characterization
of high affinity binding sites for vasopressin and oxytocin in the rat
brain by light microscopic autoradiography. Brain Res 442:105108[CrossRef][Medline]
-
Brinton RE, Wamsley JK, Gee KW, Wan YP, Yamamura
HI 1984 3H-oxytocin binding sites in the rat brain
demonstrated by quantitative light microscopic autoradiography. Eur
J Pharmacol 102:365367[CrossRef][Medline]
-
DeKloet E, Rotteveel F, Voorhuis T, Terlou M 1985 Topography of binding sites for neurohypophyseal hormones in rat brain.
Eur J Pharmacol 110:113[CrossRef][Medline]
-
Tribollet E, Audiger S, Dubois-Dauphin M, Dreifuss
JJ 1990 Gonadal steroids regulate oxytocin receptors but not
vasopressin receptors in the brain of male and female rats. An
autoradiographic study. Brain Res 511:129140[CrossRef][Medline]
-
Bale TL, Dorsa DM 1995 Effects of testosterone and
its metabolites on oxytocin receptor mRNA expression in the
ventromedial hypothalamus in male rats. Endocrinology 136:51355138[Abstract]
-
Bale TL, Dorsa DM 1995 Sex differences in and
effects of estrogen on oxytocin receptor mRNA expression in the
ventromedial hypothalamus. Endocrinology 136:2732[Abstract]
-
Stevenson KR, Riley PR, Stewart HJ, Flint AP, Wathes
DC 1994 Localization of oxytocin receptor mRNA in the ovine uterus
during the oestrous cycle and early pregnancy. J Mol Endocrinol 12:93105[Abstract/Free Full Text]
-
Larcher A, Neculcea J, Breton C, Arslan A, Rozen F,
Russo C, Zingg HH 1995 Oxytocin receptor gene expression in the
rat uterus during pregnancy and the estrous cycle and in response to
gonadal steroid treatment. Endocrinol 136:53505356[Abstract]
-
De Kloet ER, Voorhuis DAM, Elands J 1985 Estradiol
induces oxytocin binding sites in rat hypothalamic ventromedial
nucleus. Eur J Pharmacol 118:185186[CrossRef][Medline]
-
DeKloet ER, Voorhuis DAM, Boschma Y, Elands J 1986 Estradiol modulates density of putative oxytocin receptors in
discrete rat brain regions. Neuroendocrinology 44:415421[Medline]
-
Johnson AE, Coirini H, McEwen BS, Insel TR 1989 Testosterone modulates oxytocin receptor binding in the hypothalamus of
castrated male rats. Neuroendocrinology 50:199203[Medline]
-
Johnson AE, Coirini H, Insel TR, McEwen BS 1991 The
regulation of oxytocin receptor binding in the ventromedial
hypothalamic nucleus by testosterone and its metabolites. Endocrinology 128:891896[Abstract]
-
Schumacher M, Coirini H, Johnson AE, Flanagan LM,
Frankfurt M, Pfaff DW, McEwen BS 1993 The oxytocin receptor: a
target for steroid hormones. Regulatory Peptides 45:115119[CrossRef][Medline]
-
Bale TL, Dorsa DM, Johnston CA 1995 Oxytocin
receptor mRNA in the ventromedial hypothalamus during the estrous
cycle. J Neuroscience 15:50585064[Abstract]
-
Rozen F, Russo C, Banville D, Zingg HH 1995 Structure, characterization, and expression of the rat oxytocin
receptor gene. Proc Natl Acad Sci USA 92:200204[Abstract/Free Full Text]
-
Kimura T, Osamu T, Kensaku M, Brownstein MJ, Okayama
H 1992 Structure and expression of a human oxytocin receptor.
Nature 356:526529[CrossRef][Medline]
-
Inous T, Kimura T, Azuma C, Inazawa J, Takemura M,
Kikuchi T, Kubota Y, Ogita K, Saji F 1994 Structural organization
of the human oxytocin receptor gene. J Biol Chem 269:3245132456[Abstract/Free Full Text]
-
Adan RAH, Van Leeuwen FW, Sonnemans MAF, Brouns M,
Hoffman G, Verbalis JG, Burbach JPH 1995 The rat oxytocin receptor
in brain, pituitary, mammary gland and uterus: partial sequence and
immunocytochemical localization. Endocrinology 136:40224028[Abstract]
-
Murdoch FE, Meier DA, Furlow JD, Grunwald KA, Gorski
J 1990 Estrogen receptor binding to a DNA response element
in vitro is not dependent upon estradiol. Biochem 29:83778385[CrossRef][Medline]
-
LHorset F, Blin C, Colnot S, Lambert M, Thomasset M,
Perret C 1994 Calbindin-D9k gene expression in the uterus: study
of the two messenger ribonucleic acid species and analysis of an
imperfect estrogen-responsive element. Endocrinology 134:1118[Abstract]
-
Wu WX, Verbalis JG, Hoffman GE, Derks JB, Nathanielsz
PW 1996 Characterization of oxytocin receptor expression and
distribution in the pregnant sheep uterus. Endocrinology 137:722728[Abstract]
-
Ito Y, Kobayyashi T, Kimura T, Matsuura N, Wakasugi E,
Takeda T, Shimano T, Kubota Y, Nobunaga T, Makino Y, Azuma C, Saji
F, Monden M 1996 Investigation of the oxytocin receptor expression
in human breast cancer tissue using newly established monoclonal
antibodies. Endocrinology 137:773779[Abstract]
-
Taylor AH, Ang VYT, Jenkins JS, Silverlight JJ, Coombes
RC, Lqumani YA 1990 Interaction of vasopressin and oxytocin with
human breast carcinoma cells. Cancer Res 50:78827886[Abstract/Free Full Text]
-
Cassoni P, Sapino A, Negro F, Bussolati G 1994 Oxytocin inhibits proliferation of human breast cancer cell lines.
Virchows Arch 425:467472[Medline]
-
Ito Y, Kobayashi T, Kimura T, Matsuura N, Wakasugi
E, Takeda T, Shimano T, Kubota Y, Nobunaga T, Makino Y, Azuma C, Saji
F, Monden M 1996 Investigation of the oxytocin receptor expression
in human breast cancer tissue using newly established monoclonal
antibodies. Endocrinology 137:773779
-
Cassoni P, Sapino A, Papotti M, Bussolati G 1996 Oxytocin and oxytocin-analogue F314 inhibit cell proliferation and
tumor growth of rat and mouse mammary carcinomas. Int J Cancer 66:817820[CrossRef][Medline]
-
Alexander MJ, Kiraly ZJ, Leeman SE 1991 Sexually
dimorphic distribution of neurotensin/neuromedin N mRNA in the rat
preoptic area. J Comp Neurol 311:8496[CrossRef][Medline]
-
Cutler RE, Maizels ET, Hunzicker-Dunn M 1994 Delta
protein kinase-C in the rat ovary: estrogen regulation and
localization. Endocrinology 135:16691678[Abstract]
-
Astruc ME, Chabret C, Bali P, Gagne D, Pons M 1995 Prolonged treatment of breast cancer cells with antiestrogens increases
the activating protein-1-mediated response: involvement of the estrogen
receptor. Endocrinology 136:824832[Abstract]
-
Martinez-Lacaci I, Saceda M, Plowman GD, Johnson GR,
Normanno N, Salomon DS, Dickson RB 1995 Estrogen and phorbol
esters regulate amphiregulin expression by two separate mechanisms in
human breast cancer cell lines. Endocrinology 136:39833992[Abstract]
-
Aronica SM, Kraus WL, Katzenellenbogen BS 1994 Estrogen action via the cAMP signaling pathway: stimulation of
adenylate cyclase and cAMP-regulated gene transcription. Proc Natl Acad
Sci USA 91:85178521[Abstract/Free Full Text]
-
Chiang JYL, Yang TP, Wang DP 1992 Cloning and
5'-flanking sequence of a rat cholesterol 7
-hydroxylase gene.
Biochim Biophys Acta 1132:337339[Medline]
-
Archer TK, Lee H L, Cordingley MG, Mymryk JS, Fragoso G,
Berard DS, Hager GL 1994 Differential steroid hormone induction of
transcription from the mouse mammary tumor virus promoter. Mol
Endocrinol 8:568576[Abstract]
-
Archer TK, Zaniewski E, Moyer ML, Nordeen SK 1994 The differential capacity of glucocorticoids and progestins to alter
chromatin structure and induce gene expression in human breast cancer
cells. Mol Endocrinol 8:11541162[Abstract]
-
Archer TK, Fryer CJ, Lee HL, Zaniewski E, Liang T,
Mymryk JS 1995 Steroid hormone receptor status defines the MMTV
promoter chromatin structure in vivo. J Steroid Biochem 53:421429
-
Bale TL, Pedersen CA, Dorsa DM 1995 CNS oxytocin
receptor mRNA expression and regulation by gonadal steroids. In:
Advances in Experimental Medicine and Biology. Plenum Press, New York,
vol 395:269280
This article has been cited by other articles:

|
 |

|
 |
 
K. Vagnerova, I. P. Koerner, and P. D. Hurn
Gender and the Injured Brain
Anesth. Analg.,
July 1, 2008;
107(1):
201 - 214.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. A. Champagne, I. C. G. Weaver, J. Diorio, S. Dymov, M. Szyf, and M. J. Meaney
Maternal Care Associated with Methylation of the Estrogen Receptor-{alpha}1b Promoter and Estrogen Receptor-{alpha} Expression in the Medial Preoptic Area of Female Offspring
Endocrinology,
June 1, 2006;
147(6):
2909 - 2915.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. G. W. Fleming, T. E. Spencer, S. H. Safe, and F. W. Bazer
Estrogen Regulates Transcription of the Ovine Oxytocin Receptor Gene through GC-Rich SP1 Promoter Elements
Endocrinology,
February 1, 2006;
147(2):
899 - 911.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. V. Nantermet, P. Masarachia, M. A. Gentile, B. Pennypacker, J. Xu, D. Holder, D. Gerhold, D. Towler, A. Schmidt, D. B. Kimmel, et al.
Androgenic Induction of Growth and Differentiation in the Rodent Uterus Involves the Modulation of Estrogen-Regulated Genetic Pathways
Endocrinology,
February 1, 2005;
146(2):
564 - 578.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
V. Terzidou, S. R. Sooranna, L. U. Kim, S. Thornton, P. R. Bennett, and M. R. Johnson
Mechanical Stretch Up-Regulates the Human Oxytocin Receptor in Primary Human Uterine Myocytes
J. Clin. Endocrinol. Metab.,
January 1, 2005;
90(1):
237 - 246.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. O'Lone, M. C. Frith, E. K. Karlsson, and U. Hansen
Genomic Targets of Nuclear Estrogen Receptors
Mol. Endocrinol.,
August 1, 2004;
18(8):
1859 - 1875.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. E. Spencer, G. A. Johnson, R. C. Burghardt, and F. W. Bazer
Progesterone and Placental Hormone Actions on the Uterus: Insights from Domestic Animals
Biol Reprod,
July 1, 2004;
71(1):
2 - 10.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. A. Mitchell, T. C. Ting, S. Wong, B.F. Mitchell, and S. J. Lye
Parathyroid Hormone-Related Protein Treatment of Pregnant Rats Delays the Increase in Connexin 43 and Oxytocin Receptor Expression in the Myometrium
Biol Reprod,
August 1, 2003;
69(2):
556 - 562.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Vasudevan, S. Ogawa, and D. Pfaff
Estrogen and Thyroid Hormone Receptor Interactions: Physiological Flexibility by Molecular Specificity
Physiol Rev,
October 1, 2002;
82(4):
923 - 944.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. L. Siebel, H. M. Gehring, and L. J. Parry
Effects of Fetectomy on Oxytocin Receptors in the Myometrium of the Tammar Wallaby
Biol Reprod,
October 1, 2002;
67(4):
1242 - 1249.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. K. Bachir, J.-N. Laverriere, and R. Counis
Isolation and Characterization of a Rat Nitric Oxide Synthase Type I Gene Promoter that Confers Expression and Regulation in Pituitary Gonadotrope Cells
Endocrinology,
November 1, 2001;
142(11):
4631 - 4642.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. L. Bale, A. M. Davis, A. P. Auger, D. M. Dorsa, and M. M. McCarthy
CNS Region-Specific Oxytocin Receptor Expression: Importance in Regulation of Anxiety and Sex Behavior
J. Neurosci.,
April 1, 2001;
21(7):
2546 - 2552.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Gimpl and F. Fahrenholz
The Oxytocin Receptor System: Structure, Function, and Regulation
Physiol Rev,
April 1, 2001;
81(2):
629 - 683.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. A. Shapiro, C. Xu, and D. M. Dorsa
Differential Transcriptional Regulation of Rat Vasopressin Gene Expression by Estrogen Receptor {alpha} and {beta}
Endocrinology,
November 1, 2000;
141(11):
4056 - 4064.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F.-l. Tan, S. J. Lolait, M. J. Brownstein, N. Saito, V. MacLeod, D. A. Baeyens, P. R. Mayeux, S. M. Jones, and L. E. Cornett
Molecular Cloning and Functional Characterization of a Vasotocin Receptor Subtype That Is Expressed in the Shell Gland and Brain of the Domestic Chicken
Biol Reprod,
January 1, 2000;
62(1):
8 - 15.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
J. A. Copland, Y.-J. Jeng, Z. Strakova, K. L. Ives, M. R. Hellmich, and M. S. Soloff
Demonstration of Functional Oxytocin Receptors in Human Breast Hs578T Cells and Their Up-Regulation through a Protein Kinase C-Dependent Pathway
Endocrinology,
May 1, 1999;
140(5):
2258 - 2267.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
C.-W. Ou, Z.-Q. Chen, S. Qi, and S. J. Lye
Increased Expression of the Rat Myometrial Oxytocin Receptor Messenger Ribonucleic Acid during Labor Requires Both Mechanical and Hormonal Signals
Biol Reprod,
November 1, 1998;
59(5):
1055 - 1061.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
Y.-J. Jeng, S. J. Lolait, and M. S. Soloff
Induction of Oxytocin Receptor Gene Expression in Rabbit Amnion Cells
Endocrinology,
August 1, 1998;
139(8):
3449 - 3455.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. M. Hazzard, K. L. Pinckard, and F. Stormshak
Impact of Chronic Treatment of Ewes with Estradiol-17ss or Progesterone on Oxytocin Receptor Gene Transcription and Ovarian Oxytocin Secretion
Biol Reprod,
July 1, 1998;
59(1):
105 - 110.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
A.-R. Fuchs, P. Drolet, M. A. Fortier, M. Balvers, and M. J. Fields
Ontogeny of Oxytocin Receptors and Oxytocin-Induced Stimulation of Prostaglandin Synthesis in Prepubertal Heifers
Endocrinology,
June 1, 1998;
139(6):
2755 - 2764.
[Abstract]
[Full Text]
[PDF]
|
 |
|